Although other combinations of compounds were used, combined treatment of exenatide and with dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, showed to improve markers associated with liver steatosis and fibrosis in type 2 diabetes patients compared to either exenatide or dapagliflozin administration alone (Gastaldelli et al., 2020). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.